Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 29

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 29
---
 Company may
offer and sell shares of its Common Stock, with an aggregate offering amount sold of up to $100,000,000. As of the date of filing of
this Form 10-Q, the Company has sold a total of 3,218,300 shares of its common stock, at a weighted average price of $2.12 for total
proceeds of $6,553,207, net of costs of $272,092

We
have incurred significant losses and negative cash flows from operations since inception and expect to incur additional losses until
such time that we can generate significant revenue and profit, which we do not expect to occur in the near future. We had negative cash
flow from operations of approximately $2.5 million for the nine months ended September 30, 2025. As of September 30, 2025, we had cash
and cash equivalents of approximately $7.3 million and an accumulated deficit of approximately $38.9 million.

We
currently expect that our cash and cash equivalents will only be sufficient to fund our operations, development plans, and capital expenditures
through the third quarter of 2026. As such, there is substantial doubt about the Company’s ability to continue as a going concern.

We
did not have any material non-cancellable contractual obligations as of September 30, 2025.

18

Cash
Flows

The
following table provides information regarding our cash flows for the periods presented:

    Nine Months Ended 

    September 30, 

    2025  
    2024 
  
    Net cash provided by (used in): 

    Operating activities 
    $(2,486,841) 
    $(4,464,620)
  
    Financing activities 
     8,550,008  
     5,298,027 
  
    Net change in cash 
    $6,063,167  
    $833,407 

Net
Cash from Operating Activities

The
cash used in operating activities resulted primarily from our net losses, stock-based compensation expenses and changes in components
of accounts payable, accrued liabilities, and prepaid expenses.

For
the nine months ended September 30, 2025, operating activities used $2.5 million of cash, primarily due to a net loss of $8.4 million,
stock compensation costs of $6.1 million and a $0.3 million change in accounts payable, accrued liabilities and prepaid expenses. Accounts
pay